CD8A and metabolic dysfunction-associated steatohepatitis: Abou-Alfa et al[22] discovered a connection between an increase in hepatic CD8+PD1+ T cells caused by immunotherapy and the impairment of immune surveillance, leading to hepatocarcinogenesis in a mouse model of nonalcoholic steatohepatitis.